智通财经网·2026-03-30 13:57Core Viewpoint - Zhaoyan New Drug (06127) reported a revenue of 1.658 billion RMB for the year ending December 31, 2025, representing a year-on-year decrease of 17.9% [1] Financial Performance - The company's net profit attributable to equity shareholders reached 298 million RMB, showing a significant year-on-year increase of 302.1% [1] - Basic earnings per share were reported at 0.40 RMB [1] - A proposed final dividend of 0.12 RMB per ordinary share was announced [1] Order Status - The total order backlog for the reporting period was approximately 2.6 billion RMB [1] - New signed orders during the period also amounted to approximately 2.6 billion RMB [1] Revenue Decline Factors - The decrease in revenue was primarily driven by a decline in project unit prices due to earlier intense competition [1]